Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers

Inclusion criteria

• Age >= 20 and <= 35 years
• Weight: BMI > 17.6 and < 26.4 (Weight (kg) / Height (m)2)
• Subjects judged by the investigator to be eligible as study subjects, with no clinically significant findings after screening
• Subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent

Exclusion criteria

• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
• Chronic or relevant acute infections
• History of hepatic disorder (e.g., biliary cirrhosis, cholestasis)
• History of serious renal disorder
• History of or present bilateral renal artery stenosis or lack of unilateral kidney accompanying arterial stenosis
• History of or present cerebrovascular disorder
• History of hyperkalemia
• History of hypersensitivity to active ingredient (Telmisartan) or other angiotensin II receptor antagonists
• History of or present orthostatic hypotension or faint
• Surgery of gastrointestinal tract (except appendectomy)
• History of alcohol or drug abuse
• Participation to another trial with an investigational drug within 4 months prior to the trial
• Whole blood donation more than 400 mL within 3 months prior to the trial
• Whole blood donation more than 100 mL within 1 month prior to the trial
• Donation of constituent of blood of more than 400 mL within 1 month prior to the trial
• Any medication which might influence the result of the trial within 10 days prior to the trial
• Excessive physical activities within 7 days prior to the trial
• Alcohol drinking within 3 days prior to the trial
• Inability to comply with restriction of protocol
• Other than above, those who are judged by the investigator to be inappropriate as the subjects of the study